uniQure Announces Recommendation From Data Safety Monitoring Board In Phase I/II Clinical Trial Of AMT-130; No Significant Safety Concerns Observed In First Four Patients Enrolled In Higher-Dose Cohort, Enrollment Expected to be Completed By Mid-2022